FDA Reviews, Acquisitions, Dividends, and Drug Study Results Highlight Solid Growth for Major Drug Companies - Research Report on Pfizer, Johnson & Johnson, Zoetis, AbbVie, and Lilly

NEW YORK, June 26, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), Zoetis Inc. (NYSE: ZTS), AbbVie Inc. (NYSE: ABBV), and Eli Lilly and Company (NYSE: LLY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On June 21, 2013, Pfizer Inc. (Pfizer) announced that the US Food and Drug Administration (FDA) has accepted the review of a supplemental New Drug Application (sNDA) for the XELJANZ (tofacitinib citrate) rheumatoid arthritis (RA) indication. The sNDA seeks to expand the label to include inhibition of progression of structural damage. Pfizer reported that XELJANZ 5mg twice daily was approved by the US FDA in November 2012. The Company is expecting the US FDA to conclude its review of the NDA and provide a decision by February 2014, based on the anticipated Prescription Drug User Free Act (PDUFA) action date for the sNDA. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/db02_PFE]

--

Johnson & Johnson Research Report

On June 17, 2013, Johnson & Johnson announced that it has entered into a definitive agreement for the acquisition of Aragon Pharmaceuticals, Inc., which is a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. Johnson & Johnson reported that the acquisition will include Aragon Pharmaceuticals' androgen receptor antagonist program. Under the terms of the agreement, Johnson & Johnson will make an upfront cash payment of $650 million, plus additional contingent payments of up to $350 million based on certain predetermined milestones. Peter F. Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology for Janssen Research & Development, LLC, said, "The acquisition of Aragon further enhances our leadership in prostate cancer drug development. ARN-509 complements ZYTIGA and provides the potential for exciting, novel approaches to treat prostate cancer patients." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/0ba3_JNJ]

--

Zoetis Inc. Research Report

On June 20, 2013, Zoetis Inc. (Zoetis) announced that its Board of Directors has declared the Q3 2013 dividend. The Board of Directors approved a quarterly dividend of c.$0.07 per common share, which is payable on September 2, 2013 to shareholders on record as of August 1, 2013. The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/7e28_ZTS]

--

AbbVie Inc. Research Report

On June 17, 2013, AbbVie Inc. (AbbVie) presented the preliminary results of the Phase I study for ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), and in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) at the 18th Congress of the European Hematology Association (EHA) in Stockholm, Sweden. Gary Gordon, M.D., Divisional Vice President of Oncology Clinical Development at AbbVie, stated, "The preliminary data presented at EHA further support the ongoing clinical trial program for ABT-199/GDC-0199 via the BCL-2 pathway." Professor Andrew Roberts, Hematologist at the Royal Melbourne Hospital and head of Clinical Translation at the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, commented, "High-risk CLL patients are a challenging subgroup to treat, as they tend to have disappointing results with conventional chemotherapy regimens. While still early in the development process, preliminary response rates observed in these patients appear similar to those observed in other CLL patients being treated with ABT-199/GDC-0199. These data justify further investigation of this compound in patients with 17p deletion and fludarabine-refractory CLL." The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/2433_ABBV]

--

Eli Lilly and Company Research Report

On June 22, 2013, Eli Lilly and Company (Lilly) announced the detailed safety and efficacy results from three Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes. Guillermo Umpierrez, M.D., Professor of Medicine, Division of Endocrinology, Metabolism, Emory University School of Medicine, and Chief of Diabetes and Endocrinology, Grady Memorial Hospital, stated, "Dulaglutide not only demonstrated superior glycemic control in these Phase III trials, it provided this control with once-weekly dosing, which may be attractive to both patients and healthcare professionals. It's encouraging news for this investigational GLP-1 receptor agonist." Sherry Martin, M.D., Senior Medical Director, Lilly Diabetes added, "These results are a promising step forward in our effort to provide a new, once-weekly GLP-1 treatment option, giving patients another choice to help manage their diabetes." The Full Research Report on Eli Lilly and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/937b_LLY]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports